← Back to Search

Overfeeding Effects on Obesity (EAT 2 Trial)

N/A
Recruiting
Led By Ursula White, Ph.D.
Research Sponsored by Pennington Biomedical Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and pre-menopausal women 18-42 years of age
Be between 18 and 65 years old
Must not have
Chronic use of prescription weight loss medications or over the counter weight loss medications which will impact the study
Previous bariatric or other surgeries for obesity
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at how fat tissue changes when people gain weight, and how this affects their health.

Who is the study for?
This trial is for men and pre-menopausal women aged 18-42 with a BMI of 25-30, willing to follow study procedures, maintain physical activity levels, drink labeled water for research, and use contraception if necessary. Excluded are those pregnant or planning pregnancy soon, with diabetes or high fasting blood glucose, high blood pressure, eating disorders, certain medication usage including weight loss drugs or antidepressants less than 3 months old.
What is being tested?
The study tests how short-term weight gain affects the ability of subcutaneous fat tissue to expand and remodel. Participants will be randomly assigned to either continue their normal diet (control group) or increase their calorie intake by 30% (overfeeding group), examining impacts on metabolic health outcomes.
What are the potential side effects?
There may not be direct side effects from the interventions as this is an observational study; however overfeeding could potentially lead to temporary weight gain and associated discomforts like bloating. Long-term risks include potential changes in metabolism or increased risk for obesity-related conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man or a pre-menopausal woman aged 18-42.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I regularly use weight loss medications that could affect the study.
Select...
I have had surgery for weight loss.
Select...
I do not have major organ disease or significant liver problems.
Select...
I have had a partial or full hysterectomy.
Select...
I have diabetes or my fasting blood sugar is over 110 mg/dL.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adipose tissue expansion and remodeling -- in vivo adipocyte formation
Secondary study objectives
Adipose tissue expansion and remodeling -- in vivo triglyceride synthesis
Cardiometabolic health outcomes

Side effects data

From 2012 Phase 4 trial • 200 Patients • NCT01342510
30%
Pain with injection of propofol
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lidocaine/Magnesium
Control
Lidocaine
Magnesium

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: OverfeedingExperimental Treatment1 Intervention
The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
Group II: ControlExperimental Treatment1 Intervention
The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Control
2011
Completed Phase 4
~15780
Overfeeding
2016
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

Pennington Biomedical Research CenterLead Sponsor
309 Previous Clinical Trials
180,074 Total Patients Enrolled
4 Trials studying Metabolic Syndrome
207 Patients Enrolled for Metabolic Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,443 Previous Clinical Trials
4,331,086 Total Patients Enrolled
35 Trials studying Metabolic Syndrome
2,882 Patients Enrolled for Metabolic Syndrome
Ursula White, Ph.D.Principal Investigator - Pennington Biomedical Research Center
Pennington Biomedical Research Center
1 Previous Clinical Trials
11 Total Patients Enrolled

Media Library

Control Clinical Trial Eligibility Overview. Trial Name: NCT04583514 — N/A
Metabolic Syndrome Research Study Groups: Control, Overfeeding
Metabolic Syndrome Clinical Trial 2023: Control Highlights & Side Effects. Trial Name: NCT04583514 — N/A
Control 2023 Treatment Timeline for Medical Study. Trial Name: NCT04583514 — N/A
~12 spots leftby Dec 2025